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ABSTRACT 
 
Background: Retention in HIV care is critical to ensure timely treatment initiation, viral 
suppression, reduced transmission, and to prevent AIDS-related deaths. Retention in care 
is low and falls short of the level needed to meet the UNAIDS 90-90-90 targets. There 
are few interventions designed to improve retention in HIV care and quantifying retention 
in care has been mostly limited to quantifying ‘retention in clinic’. ‘Retention in clinic’ 
accounts for those who return to the clinic at which they were originally enrolled but does 
not consider informal or formal transfers, which are common in sub-Saharan Africa. The 
overall aim of this thesis was to quantify retention in HIV care and to investigate whether 
the WelTel text-messaging intervention, previously found to improve antiretroviral 
therapy adherence, improved retention during the first year of HIV care. Ancillary studies 
using baseline data were also conducted as part of this thesis. 
 
Methods: Between April 2013 and June 2015, adults testing HIV-positive were recruited 
at two clinics in informal settlements in Nairobi, Kenya. Individuals ineligible for the 
trial because they did not meet phone-related trial eligibility criteria were invited to 
participate in a supplementary cohort study. In the trial, intervention arm participants 
received a weekly text-message and were asked to respond within 48 hours. The primary 
outcome was retention in care at 12-months (clinic attendance 10-14 months after the 
first visit). Participants who did not attend this 12-month appointment were traced and 
those confirmed active in care elsewhere were considered retained. All participants, both 
in the trial and cohort study, were followed for up to 14 months to quantify retention in 
care at one year. Baseline data for the entire study population were used to conduct 
additional studies on advanced HIV at presentation to care and a gender analysis of 
health-related quality of life at the time of a positive HIV test. 
 
Results: Of 700 individuals recruited for the trial, 349 were allocated to the intervention 
and 351 to the control arm. At 12 months, 79.4% (n=277/349) of intervention arm 
participants were retained in care compared to 81.2% (n=285/351) of control arm 
participants (risk ratio 0.98, 95% confidence interval [CI] 0.91 – 1.05). In the larger 
cohort study (n=775), 62.7% (95% CI 59.2% - 66.1%) of participants returned to the 
clinic for their 12-month appointment (retained in clinic) and 609 (78.6%, 95% CI 75.7% 
- 81.5%) were retained in care at any HIV clinic. In the first ancillary study, 248/753 
(32.9%) participants presented to care with advanced HIV, 59.0% (146/248) of whom 
had been previously diagnosed with HIV. In the second ancillary study, the mean 
physical composite score was statistically significantly higher in women than men at the 
time of an HIV diagnosis (adjusted mean difference [AMD] 2.49, 95% CI 0.54 - 4.44). 
There was no significant difference between the genders in mental composite scores 
(AMD -0.99, 95% CI -2.71 - 0.73). 
 
Conclusions: Presentation to care with advanced HIV was primarily due to delayed 
diagnosis, rather than delayed linkage to care after diagnosis. Variation by clinic suggests 
that outreach and other community-based efforts may drive earlier testing and linkage to 
care. After receiving a positive HIV test, men and women had similar mental health 
scores, while women reported greater physical health. The weekly WelTel text-
messaging service did not improve retention in early HIV care in this setting. Both in the 
trial and cohort study, retention in clinic substantially underestimated retention in care 
one year after presenting to care. While the proportion of patients retained in care was 
greater than expected, interventions to improve retention in care are needed to meet 
global targets to end the AIDS epidemic. 
 
Keywords: HIV, mHealth, retention in care, Kenya, informal settlement, randomized 
controlled trial, health-related quality of life, advanced HIV 
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1. INTRODUCTION  
1.1. HIV 
 
Human immunodeficiency virus (HIV) is believed to have originated in Kinshasa, in the 
Democratic Republic of Congo around 1930, when HIV crossed species from 
chimpanzees to humans. The current epidemic did not start until the mid to late 1970s. In 
the 1980s in the United States, cases of Kaposi’s sarcoma and pneumocystis carinii 
pneumonia were reported in young, previously healthy men, which ultimately led to the 
recognition of Acquired Immune Deficiency Syndrome (AIDS) as a disease. AIDS was 
found in every continent, and by the end of the decade, the World Health Organization 
(WHO) reported that were 400,000 cases worldwide (1). 
 
In 2017, there were 36.9 million (31.1 million - 43.9 million) people living with HIV (2). 
Groups at high risk of infection include men who have sex with men, people who inject 
drugs, female sex workers and transgender women. Almost 2 million people were 
infected with the virus in 2017 (1.8 million [1.4 – 2.4 million]); however, this is a 47% 
decrease since the peak of the epidemic in 1996 (2). Sub-Saharan Africa bears the brunt 
of the burden of the epidemic, with the largest number of people living with HIV. Both 
globally and in East and Southern Africa, there are increasing numbers of people on 
treatment. In 2017, 21.7 million (19.1 – 22.6 million) were accessing therapy (2). The 
scale-up of antiretroviral treatment (ART) programmes in South and East Africa over the 
last decade has led to 60% of those with HIV in the region being on treatment (3). 
 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) aims to end the AIDS 
epidemic by 2030. Concretely, by 2020, three targets have been set: to have 90% of 
people living with HIV know their status; 90% of those diagnosed with HIV on ART; 
and 90% of people receiving ART virally suppressed (4). To meet the first target, more 
frequent testing is required, as well as testing targeted to key populations and broader 
testing services, such as integrating testing with other care services and self-testing. Once 
people are aware of their status, it is critical to treat people with HIV. ART prevents 
illness and death, averts new infections, and has substantial economic benefits (through 
preventing new infections, increased labour productivity, and decreased need for orphan 
care and medical costs). To achieve the 3rd 90, long-term retention in care is essential, 
including re-engaging those who drop out of care. 
 
1.2. HIV in Kenya 
 
The first case of HIV in Kenya was detected in 1984. Towards the end of 1987, HIV 
began to spread rapidly, and by 1999, HIV was declared a national disaster. Currently, 
Kenya has the fourth largest HIV epidemic in the world. In 2017, there were 1.5 million 
(1.3– 1.8 million) people living with HIV in the country (Figure 1), with a prevalence of 
4.8% (4.0 – 5.8%) among adults aged 15 to 49 years (5). HIV infection is more prevalent 
in women than men throughout Africa, and in Kenya  860,000 (730,000 - 1,000,000) 
women are living with HIV compared to 520,000 (430,000-630,000) men (5). More 
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women than men are also on treatment. In 2017, 65% (49 – 80%) women aged 15 years 
and older were receiving ART compared to 53% (38 – 66%) of men (UNAIDS 2019). 
 
Figure 1. People living with HIV in Kenya 
 
 
 
Kenya’s epidemic, driven by heterosexual sexual transmission, is considered generalized 
as it is firmly established in the general population; however, there are groups who are 
especially vulnerable to infection. The groups most affected include female sex workers; 
men who have sex with men; people who inject drugs; and adolescents and young people 
(age 15 to 24 years), particularly women. Forced sex and sexual violence have made 
young women vulnerable to HIV infection (6). Compared to adults, the likelihood of 
adolescents and young people initiating and staying on treatment is low, and AIDS 
remains the leading cause of death in Kenya among young people (7). Female sex 
workers, men who have sex with men, and people who inject drugs face stigma, 
discrimination and violence in Kenya. Stigma and the criminalization of homosexuality 
are barriers to seeking treatment for people with HIV, and often for health care workers 
providing care to members of these groups. 
 
HIV prevalence also varies geographically, from a high in Homa Bay County in the 
Nyanza region of 26% to a low in Wajir County in the North East region of 0.4% (8). 
Prevalence also varies between urban and rural areas, with a higher prevalence in urban 
areas. Within urban areas, differences are found between slum and non-slum populations. 
In Nairobi, 12% of slum residents are HIV positive compared to 5% of non-slum 
residents, and the gap in HIV prevalence between males and females narrows in slum 
areas (9). 
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Figure 2. New HIV infections in Kenya over time 
 
 
 
Between 2010 and 2017, there was a 32% reduction in new infections (Figure 2) and a 
48% reduction in AIDS-related deaths (5). This is due to treatment and the success of 
several prevention programmes in Kenya, including condom availability and use, 
prevention of mother-to-child transmission programmes (PMTCT), HIV education and 
awareness, voluntary male circumcision and pre-exposure prophylaxis. For Kenya to 
continue to curb the HIV epidemic, stigma and discrimination need to be reduced, 
successful HIV prevention and treatment programmes require scaling, and sustainable 
funding must be ensured. 
 
Health Care in Kenya 
 
In Kenya, there is a mix of the private and public health care (Figure 3). The public sector 
is run by the Ministry of Public Health and other government institutions. The private 
sector is made up of for-profit and not-for-profit organizations, including local and 
international non-governmental organizations (NGOs), faith-based organizations (FBOs) 
and community-based organizations (CBOs). Private hospitals are found mainly in 
Nairobi and Mombasa, with private clinics found in most urban centres. 
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Figure 3. Health care in Kenya 
 
 
 
Government-provided health care consists of hospitals, health centres, 
dispensaries and community health units (Figure 4). Hospitals offer 
curative services while at the sub-district level, health promotion and 
prevention services are offered. The district hospitals are the first 
referral centre. Health centres are typically staffed by midwives, 
nurses, clinical officers and occasionally physicians. These 
centres offer basic curative, preventative and reproductive 
health services. Dispensaries are run by registered nurses. 
There are also traditional medicine practitioners and 
individuals and communities who ensure care and 
support for their families and their broader 
community. 
 
HIV puts on enormous strain on Kenya’s 
healthcare system and is the leading cause of 
death. HIV and AIDS are the reason for more 
than half of all hospital admissions (9). 
Kenya’s HIV response is still funded primarily by donors. There is a significant and 
growing funding gap to meet the UNAIDS 90-90-90 targets by 2020 as external funding 
is flat-lining or decreasing. This is despite the government of Kenya doubling its funding 
towards the HIV and AIDS response between 2007 and 2013 (10). In addition, Kenya is 
now classified as a middle-income country, which changes their eligibility for funding. 
To meet targets, the government of Kenya will need to substantially increase its 
allocation to the response (11), which may not be feasible. The government of Kenya 
needs to find options for sustainable funding and surmount inequities in healthcare 
provision in gender, between urban and rural populations, and between districts and 
provinces. At the same time, stigma and discrimination needs to be tackled and legal and 
structural barriers reduced. 
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1.3. Retention in HIV Care 
 
Retaining individuals in care is fundamental to the long-term success of HIV 
programmes and to meet the UNAIDS 90-90-90 targets. Yet, over 20% of patients in 
ART programmes are lost to follow-up by six months in lower-income settings (12). 
In a systematic review of studies conducted in sub-Saharan African between 2007 and 
2009, attrition at 12-months remained at 20% but by 36 months, increased to 35% 
(13). Among patients who have not yet initiated treatment, retention is even worse 
(14, 15). Retaining ART-ineligible patients is critical to reduce the high risk of 
morbidity and mortality in this population and to minimize the risk of late treatment 
initiation. Furthermore, patient retention is associated with decreased transmission 
risk behavior (16) and has the potential to contain health care costs (by capturing 
individuals before they are in need of hospital care). 
 
At the time these studies were undertaken (under the umbrella of the WelTel Retain 
trial designed to investigate the effect of text-messaging on retention in early HIV 
care), WHO’s guidelines were to initiate ART when an individual’s CD4 count 
dropped below 350 cells/mm3. In 2013, during the trial, WHO changed the guidelines 
so that people with higher CD4 counts (500 cells/mm3) were eligible for treatment. In 
2016, after the trial was complete, WHO revised guidelines to recommend that all 
individuals initiate ART, regardless of their CD4 count. Retention in care among 
individuals with HIV, irrespective of their position along a changing continuum of 
care, is imperative to prevent transmission of the virus, reduce morbidity and improve 
survival. 
 
Barriers to retention in HIV Care 
 
There are many social, structural and personal barriers to retention in HIV care. 
Transportation costs and geographical distance (17, 18) to clinic are factors, which are 
more prevalent in rural compared to urban areas and are compounded by poor terrain 
and a lack of transportation infrastructure (19). Social barriers include stigma, 
discrimination and a lack of social support (20). Many people do not want to be seen by 
people who they know when they are receiving care from a HIV clinic, so they often 
travel farther to receive care from clinics outside of their community. Barriers at the 
clinic include negative interactions with healthcare providers, who may be rude, 
unfriendly, disrespectful and patronizing. Other clinic-related barriers include long 
waiting times to see a clinician or to receive test results, concerns regarding healthcare 
providers maintaining confidentiality, and overcrowding (19). 
 
People with HIV may also have competing priorities. Attending clinic appointments 
may mean missing time from work, caring for children and domestic responsibilities, 
which may be a larger barrier to retention in care among poor families. A lack of status 
disclosure to a partner and family is associated with poor retention (18). Many males are 
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migrant workers, and travel as truck drivers, fishermen or farm workers, making 
attending the clinic for regular appointments more difficult (18). Drug and alcohol use is 
a barrier to retention in HIV care, as are misconceptions about HIV care and treatment 
(20). Feeling healthy and well is another reason people do not return to clinic (21), and 
conversely, ART toxicity and poor health is also a factor (18). 
 
Retention in clinic versus retention in care 
 
There have been several studies and reviews estimating retention in ART care in sub-
Saharan Africa (13,22,23), and to a lesser extent, retention in pre-ART care (14,23,24). 
Authors of these reviews have noted limitations of the included studies such as not 
counting patients who drop out of care and re-enter the health system, lack of reporting 
of transfers out of care (either formally or informally), and not tracing patients who are 
lost to follow-up to ascertain their status. These limitations may lead to an underestimate 
of retention in HIV care. More accurate estimates of retention in care require moving 
beyond quantifying whether individuals return to the clinic at which they originally 
enrolled (retention in clinic) to examining whether participants who did not return to the 
clinic are active in care at their original clinic or elsewhere (retention in care). 
 
Around the time we designed our cohort study to estimate retention in care, a study in 
rural Uganda using a sampling-based approach to estimate retention in HIV care beyond 
those who simply returned to the clinic was published (25). In this study, around 15% of 
the 829 participants deemed lost to follow-up were traced to ascertain their vital status 
(25). Two scenarios, an “optimistic” scenario in which traced patients found alive, but 
not interviewed, were assumed to be active in care, and a “pessimistic” scenario in 
which traced patients found to be alive, but not interviewed, were assumed to be inactive 
in care, demonstrated increased estimates of patient retention in care at one, two and 
three years compared to estimates based on retention in clinic alone (25). Since then, 
additional studies have documented the importance of using retention in care, which 
accounts for informal and formal transfers, rather than retention in clinic, when 
quantifying retention in HIV care (21,26) 
 
1.4. Mobile phones and retention in care 
 
Most mobile health (mHealth) studies in HIV care have focussed on using text messages 
to promote medication adherence. Although findings have been mixed, findings from 
meta-analyses indicate that overall, weekly text-message interventions improve 
adherence (27). Results from meta-analyses also indicate that less frequent messaging 
and messaging that requires a response from participants is more likely to be effective 
than both more frequent messaging and messages that do not require a response (27–29).  
 
There have been few studies of mHealth interventions to improve retention in HIV care. 
Most of the mHealth studies that have been done, both in and outside of Africa, have 
investigated text messages as appointment reminders rather than as a tool to improve 
retention in HIV care. Studies using one-way text message appointment reminders e.g. 
“Remember you have an appointment tomorrow.” failed to demonstrate an effect on 
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appointment attendance (30–33). Several of the studies suffered from methodological 
limitations, including small sample size (33), presenting data on individuals with HIV as 
a subgroup (32), a before-and-after study design (32), and selection bias (33). 
Conversely, two randomized controlled trials of women enrolled in PMTCT programmes 
in Kenya found that fortnightly mobile phone calls or supportive text messages (in which 
participants were given the opportunity to respond) improved retention in care (34,35). 
To my knowledge, the WelTel Retain trial was the first study in a resource-limited setting 
to test whether an interactive text-messaging service improved retention in care in a 
general population with HIV. 
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2. AIMS AND OBJECTIVES  
2.1 Overall aim  
Quantify retention in care considering informal and formal transfers of care and 
determine whether a text-messaging intervention promotes retention in care during the 
first year of HIV care in low-income settings in Kenya.  
2.2 Specific objectives 
 
1. To determine whether advanced HIV at presentation to care is due to late diagnosis or 
delays in accessing care and factors associated with it. (Study I) 
 
2. To determine if there are gender differences in health-related quality of life (HRQoL) 
among adults at the time of a positive HIV test and to examine gender-specific factors 
associated with HRQoL. (Study II) 
 
3. To quantify retention in clinic versus retention in care during the first year of HIV 
care and determine risk factors associated with attrition from care in low‐income 
settings in Nairobi, Kenya. (Study III) 
 
4. To determine whether a two-way text-messaging intervention improves retention 
during the first year of HIV care in Nairobi, Kenya. (Study IV) 
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3. METHODS  
3.1 Study design  
Studies I and II 
 
Studies I and II are analytical cross-sectional studies. They both used questionnaire data 
collected through face-to-face interviews and laboratory data collected at the baseline 
visit. Study I compared those with advanced HIV to those with non-advanced HIV at 
presentation to care. Study II compared self-perceived health-related quality-of-life data 
collected at the time of presentation to HIV care between men and women. 
 
Study III 
 
Study III is a cohort study that followed adults who tested positive for HIV from their 
baseline visit for up to 14 months. After examining study records, those who did not 
return to care were contacted by telephone or traced in the community. Those who were 
retained in care at one year versus those who were not were quantified and compared.  
 
Study IV 
 
Study IV is an unmasked, randomised, parallel-group study conducted at two clinics in 
informal settlements in Nairobi, Kenya. The trial examined whether a text-messaging 
intervention improved retention in HIV care at 12 months. 
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3.2 Setting  
The study was initially designed as a single-site 
study in Kibera, an informal settlement in 
Nairobi, Kenya. Entry to the study required a 
positive HIV test. A series of nationwide 
shortages of HIV test kits led to slower-than-
expected recruitment. To complete the study on 
time and within budget, we added a second site 
in Baba Dogo, which is another informal 
settlement in Nairobi. 
 
Kibera is the largest slum in Nairobi, covering 
2.38 km2. The population of Kibera is 170,070 
according to the 2009 Kenyan census (36), 
although estimates vary widely. Baba Dogo is 
in Nairobi’s Eastlands area. It is smaller than 
Kibera with a population of approximately 
30,000 (37). 
 
Both informal settlements lack government 
health care and their populations have minimal 
access to basic services such as education, 
water, sanitation, transportation infrastructure 
and other public services. Unemployment in both Kibera and Baba Dogo is high, and 
there is overcrowding and insecurity. HIV prevalence among adults in Kibera is 12% (38) 
compared to 5% among Nairobi’s non-slum residents (39). 
 
Between April 4th, 2013 and June 4th, 2015, we recruited participants from the Kibera 
Community Health Centre, operated by Amref Health Africa, the largest non-
governmental health organisation based in Africa (https://amref.org/home/). On Feb 
26th, 2014, recruitment began at the Baba Dogo Health Centre, operated by Partners for 
Health and Development in Africa, a non-profit organisation registered in Kenya and 
affiliated with the University of Manitoba. Recruitment at this site ended on May 27th, 
2015. Both clinics are primary comprehensive care clinics, with no direct patient costs for 
HIV or AIDS care and treatment. 
 
Participants were followed up for up to 14 months. Follow-up concluded on September 
22nd, 2016. Data were collected throughout the follow-up period. 
 
3.3 Participants  
Individuals who tested HIV-positive at the Kibera and Baba Dogo Health Centres were 
referred to a research nurse, who assessed study eligibility using a checklist. 
 
Eligibility criteria for the trial (Study IV) are listed below. 
Figure 5. Outside the Kibera 
Community Health Centre 
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Inclusion criteria: 
• HIV positive; 
• at least 18 years of age; 
• own or have access to a mobile phone and be able to use simple text messaging (or 
have somebody who could text message on their behalf). 
 
Exclusion criteria: 
• previous assessment for ART eligibility; 
• previous or current exposure to ART; 
• pregnancy. 
 
If a person met all the criteria except for the phone-related criteria, they were invited to 
participate in a supplementary cohort study (described below). Studies I, II, and III 
included all the participants enrolled in the randomised controlled trial as well as 
participants enrolled in the supplementary cohort study. 
 
3.4 Supplementary cohort study 
 
At the time of recruitment, if potential participants did not meet the trial’s phone-related 
criteria (i.e. own or have access to a mobile phone and be able to use simple text 
messaging [or have somebody who could text message on their behalf]), they were 
invited to enrol in a supplementary cohort study. The rationale for establishing a larger 
cohort involving participants who were not eligible for the trial was to establish a more 
generalizable cohort for ancillary studies than that which would have been established if 
we had used the trial population alone. Participants in the cohort study were not 
randomized to the intervention or control arm but underwent the same procedures as trial 
participants e.g. consent procedures, questionnaires, and tracing if they did not return to 
the clinic at 12 months. 
 
3.5 Intervention and randomization 
 
Participants were randomly assigned to receive the intervention in addition to usual care or 
to usual care only. Individuals participating in the cohort study only were not randomised 
and did not receive the intervention. 
 
The WelTel service consisted of weekly text-messages to check-in on how patients were 
doing and provide them the opportunity to identify whether assistance was required 
(Figure 6). Every Monday morning, a short message service (SMS) gateway sent text 
messages to intervention arm participants asking “Mambo?” (Swahili for “How are 
you?”). Participants were instructed to respond within 48 hours of receiving the message 
either that they were well (e.g. “Sawa”—Swahili for okay) or that they were having 
difficulties (e.g. “Shida”—Swahili for difficulty). The research nurses telephoned all 
participants who reported a problem or did not respond and recorded participants’ issues 
and reasons for non-response. Intervention arm participants received the intervention until 
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the earliest of the following: death; study withdrawal; or study exit. 
 
Randomization and allocation 
 
Randomization of participants to the intervention or control arm was at a 1:1 ratio, using 
random block sizes of 2, 4 and 6. Block sizes were not disclosed until publication of the 
trial. We generated the randomisation sequence using the “ralloc” command in Stata. A 
research assistant put the allocations in individual, sequentially numbered, opaque 
envelopes and sealed them. After meeting inclusion criteria, consenting to participate, and 
completing baseline assessments, participants were assigned to a study arm by a research 
nurse who opened one of the numbered envelopes to determine allocation. 
 
Usual care 
 
Control arm and cohort-study-only participants did not receive text messages from the 
automated WelTel service. Participants in the control and intervention groups, as well as the 
cohort-study-only participants, received usual care and were followed-up according to clinic 
protocol (Figure 6). Baseline laboratory testing include two rapid HIV tests. The first was 
Alere Determine HIV-1/2 (https://www.alere.com/en/home/product-details/determine-hiv-1-
2.html). Uni-Gold (http://www.trinitybiotech.com/area/uni-gold/) was used as a 
confirmatory test. CD4 counts were measured at the baseline visit and throughout the study. 
Among other services, usual care included psychosocial support and counselling, patient 
education, and treatment (Figure 6). Patients who did not attend a clinic appointment were 
called one day after a missed appointment, and if necessary, they were called a second time 
three days later. 
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Figure 6. Intervention and Usual Care 
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3.6 Data collection 
 
Experienced HIV research nurses were hired specifically for the project. Data were 
collected using study-specific instruments as well as part of routine care. After a 
confirmatory HIV test, the research nurses used an eligibility checklist to determine if a 
potential participant was eligible for the trial or supplementary cohort study. If an 
individual was eligible and willing to participate, the research nurse went through the 
consent forms with the participant and collected either written consent (if literate), or a 
thumbprint with a witness’s signature if illiterate. A piloted, validated questionnaire was 
then administered by the research nurse. The research nurses also completed a detailed 
participant locator form. The participants had the choice of conversing in English or 
Kiswahili. 
 
Baseline CD4 data reflecting the immune status of the participants were taken from 
routine data in clinical records. Throughout the study, CD4 count for each test and visit 
date data were also collected. Partway through the study, the clinics began viral load 
testing (October 2014 in Kibera and February 2015 in Baba Dogo). Viral load data were 
collected but not used in any of the studies. 
 
At six and 12 months, study-specific follow-up questionnaires were administered for all 
participants who returned to the clinic at these time points. At the end of the study, a 
tracing report form was filled out for all participants, indicating whether they returned to 
the clinic or if they did not, what type of tracing was undertaken to ascertain their status 
(telephone or community tracing). This form reported the participants’ final outcome i.e. 
retained in clinic, informally or formally transferred care, lost to follow-up, or death. 
 
Before the study began, the questionnaire was translated from English to Kiswahili, back-
translated, and pre-tested with clinic patients (n = 10). Previously validated instruments 
were used when possible, e.g. the SF-12 health-related quality of life questionnaire 
previously validated in a similar setting. Throughout the study, data were entered in 
Microsoft Access on a weekly basis. Verification procedures included cross-checking 
data files with original forms and clinical records, as well as range and consistency 
checks.  
 
For participants receiving the WelTel intervention, WelTel's technological platform 
captured outgoing weekly SMS messages and incoming participant responses and 
instances of non-response. The research nurses used the platform to record reasons why a 
participant responded with a problem or did not respond, and the actions that were taken. 
 
3.7 Ethical considerations 
 
Consent was sought from all participants in the trial and supplementary cohort study. 
After a clinic staff member introduced the study to the potential participant, a trained 
research nurse provided the potential participant with further details. If the participant 
wanted to enrol, the research nurse discussed the information in the consent form with 
them in the language in which the individual was most comfortable, English or Kiswahili. 
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Participants were given the opportunity to ask questions before providing written consent. 
Once signed, each participant was provided with a copy of the information and consent 
form. Illiterate patients who wished to participate provided consent in the presence of a 
literate witness; the participant's thumb print was used in lieu of their signature. 
 
As the study involved tracing participants by telephone or in their communities to 
determine their status at the end of the study, special ethical consideration was required. 
Aspects of the study that were unusual for research studies, i.e. including identifying 
information on study records, such as locator forms that were disseminated to outreach 
healthcare workers, needed to be explicitly stated on consent forms. 
 
The original study protocol, information and consent form, and baseline questionnaire 
were approved by the University of British Columbia Clinical Research Ethics Board 
(H12–00563) and the AMREF Ethics and Scientific Review Committee (P40/12). Ethical 
approval was renewed on an annual basis.  
3.8 Outcomes  
Table 1. Outcomes, outcome measures and methods of analysis for all four studies 
 
Outcome Outcome measure Method of analysis 
Study I   
Advanced HIV Presenting with a CD4 count <200 
cells/mm3 or at WHO stage 4 
i. Descriptive statistics 
ii. Logistic regression to 
examine factors associated 
with advanced HIV 
Study II   
Health-related quality of 
life 
SF-12 PCS and MCS scores Multiple linear regression 
Study III   
a) 12-month retention in 
clinic 
Attends 12-month clinic 
appointment at the clinic at which 
participant originally enrolled (10-14 
month timeframe) 
Descriptive statistics 
b) 12-month retention in 
care 
Attends 12-month clinic 
appointment at the clinic at which 
participant originally enrolled or 
active in care elsewhere (10-14 
month timeframe) 
i. Descriptive statistics 
ii. Generalized linear 
regression to examine factors 
associated with attrition (those 
not retained in care were 
considered lost to attrition) 
Study IV   
1.Primary outcome:   
a) 12-month retention in 
care 
Attends12-month clinic appointment 
(10-14 month timeframe) or active in 
care elsewhere 
Chi-squared test 
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2. Key secondary 
outcomes: 
  
a) Retention in Stage 1 
HIV care 
Attends clinic to receive CD4 results 
(within 3 weeks of positive HIV test) 
Chi-squared test 
3. Additional secondary 
outcomes: 
  
a) Timely initiation of 
ART 
Starts ART within 3 months of 
eligibility (for those eligible at 
baseline) 
Chi-squared test 
b) Time to ART initiation ART initiation after eligible (at 
baseline) 
Kaplan-Meier survival analysis 
c) 6-month retention in 
clinic 
Attends 6-month clinic appointment 
(5-7 month timeframe) 
Chi-squared test 
d) 12-month retention in 
clinic 
Attends 12-month clinic 
appointment (10-14 month 
timeframe) 
Chi-squared test 
e) Proportion of scheduled 
appointments kept 
Mean proportion of scheduled 
appointments attended 
T-test 
f) Satisfaction with care 5-point Likert scale item Kruskal-Wallis test 
g) Level of social support 5-point Likert scale item Kruskal-Wallis test 
h) Health-related quality of 
life 
SF-12 PCS and MCS scores T-test 
i) Death (all-cause) All-cause mortality (binary) Chi-squared test  
3.9 Statistical Methods  
Each study included descriptive statistics of participants’ baseline characteristics to 
enable comparison of groups. These statistics were reported as a mean (SD) or median 
(first quartile, third quartile) for continuous variables, and count (percent) for categorical 
variables. Baseline characteristics included: gender, age, education, CD4 count, ART 
eligibility, mobile phone access, and other variables relevant to the study. In all studies, 
descriptive analyses were conducted in SPPS versions 14 or 21, and additional analyses 
were completed using Stata version 12. Analyses were restricted to individuals with 
complete data and all p-values are two-sided. 
 
Study I 
 
Logistic regression was used to determine factors associated with advanced HIV at 
presentation to care. First, univariable analyses were performed to assess the strength of 
the association between each factor and the outcome. Variables were then included in an 
initial multivariable model if they had a univariable p-value of ≤0.25 or were considered 
important based on prior evidence (i.e. sex). In the final adjusted models, variables were 
selected based on a significance threshold of p < 0.05. Nested models were compared 
using likelihood ratio tests to examine interaction between sex and travel time, and to 
determine whether to include a linear effect or indicator variables for ordered categorical 
variables. The fit of the final model was tested with the Hosmer-Lemeshow goodness-of-
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fit test. Results are presented as estimated odds ratios (OR) and adjusted ORs (AOR) with 
corresponding 95 % confidence intervals (CI) and p-values. All p-values are two-sided 
and reported to three decimal places with those less than 0.001 reported as p < 0.001. 
 
Study II 
Multiple linear regression was used to determine whether gender was associated with 
HRQoL. Univariable analyses were performed to assess the strength of the association 
between each factor and the outcome. Variables were included in an initial multivariable 
model if they had a univariable p-value of ≤0.25 or were considered important based on 
prior evidence. Variables included in final adjusted models were selected based on a 
significance threshold of p < 0.05; however, all variables strongly associated with the 
outcome in univariate analyses were also included. 
Since gender-specific models were exploratory, all variables were included in the models. 
The adequacy of the models was evaluated by examining plots of the residuals. 
Heteroscedasticity was tested using Breusch–Pagan and White tests. Robust standard 
errors were used if heteroscedasticity was detected. Results are presented as the mean 
difference with corresponding 95% CI and p-values. 
Study III 
Generalized linear regression with a log link and binomial distribution was used to test 
whether selected factors were associated with attrition from care (rather than attrition 
from clinic). First, bivariate analyses were performed to assess the crude association 
between each factor and the outcome. Then, all variables were included in a multivariable 
model. Interaction between variables and tests of linear assumption (for variables with 
multiple categories) were examined using nested models and the likelihood ratio test. 
Results are presented as risk ratios (RR) and adjusted RRs (ARR) with corresponding 
95% CI. 
Study IV 
Analyses were by intention to treat; therefore, we included all participants according to 
the study group to which they were originally allocated, regardless of the intervention 
received, or if they were subsequently deemed ineligible. For the primary and key 
secondary endpoints, we used a χ2 test to determine if the proportions of participants 
retained in care differed between the study groups. Secondary binary outcomes were 
similarly analysed. For other secondary outcomes, we used t-tests for continuous 
variables and Kruskal–Wallis or Mann–Whitney U tests for non-normally distributed 
variables. For time-to-event outcomes, we used a Kaplan–Meier analysis and estimated 
the hazard ratio. We also assessed the proportional hazards assumption. In subgroup 
analyses, we assessed whether the intervention effect was homogeneous by including an 
interaction term between the intervention allocation and subgroup-defining variable. We 
reported p values for the interaction tests, rather than the treatment effect within groups. 
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3.10 My role in these studies 
 
While working for Dr. Richard Lester in 2011, the National Institutes of Health issued an 
AIDS-related funding opportunity announcement for innovations to optimize HIV 
retention in care. On the heels of the successful WelTel Kenya1 trial, he decided to apply 
for funding to investigate whether WelTel may be an effective retention strategy earlier 
in the continuum of HIV care. I was responsible for writing the NIH grant, including 
designing the trial (in consultation with other investigators), calculating sample size, 
proposing statistical analyses (approved by the trial statistician), and writing exhaustive 
documents on ethical considerations and other NIH requirements. 
 
When the scientists at NIH had reviewed our application, I was responsible for answering 
their queries. I consulted with other investigators when the questions lay beyond my 
realm of knowledge. 
 
In conjunction with the WelTel Retain trial, I designed a supplementary cohort study to 
investigate retention in care without the limitations associated with using a trial 
population only. The baseline data from this larger cohort study was used to examine 
advanced HIV at presentation to care and health-related quality of life, the latter being 
Professor Ekstrӧm’s idea. 
 
I was responsible for the overall management of the trial, including liaising with the Data 
Safety and Monitoring Board and the multiple institutions involved. During the trial, I 
wrote an application for additional funding and managed the interim analysis. I visited 
Nairobi numerous times to have face-to-face contact with research staff and to better 
understand the context of the study. During the study, I was responsible for data 
oversight, including data cleaning. 
 
For each study, I was principally responsible for design, statistical analysis, and writing 
the manuscript. In all instances, I submitted the manuscripts for publication and was 
responsible for making the required revisions in consultation with my co-authors and for 
the responding to the reviewers, which were quite the undertakings in the cases of the 
articles published in Lancet Public Health and the Journal of the International AIDS 
Society. 
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4. RESULTS  
4.1 Advanced HIV disease at presentation to care: late diagnosis or 
delayed linkage to care? (Study I)  
Of the 1068 HIV individuals living with HIV who were screened to participate in the 
study, 775 were recruited (700 for the trial and 75 for the cohort study only). Selected 
baseline characteristics are shown in Table 2. Approximately 1/3 (n=248/753; 32.9%) of 
the cohort presented to care with advanced HIV (CD4 count <200 cells/mm3 or WHO 
stage 4) (see appendix). 
 
Table 2. Demographic and clinical characteristics of participants in the Advanced 
HIV study, n=753, Nairobi, Kenya. 
 
Variable Non-advanced HIV at 
presentation to care 
(n=505) 
n (%) 
Advanced HIV at 
presentation to care 
(n=248) 
n (%) 
Sex   
Male 183 (61.4) 115 (38.6) 
Female 322 (70.8) 133 (29.2) 
   
Age (years)   
Mean (SD) 32 (9.22) 37 (10.26) 
<30 227 (79.9) 57 (20.1) 
30-39 178 (62.9) 105 (37.1) 
40-49 71 (57.7) 52 (42.3) 
≥50 29 (46.0) 34 (54.0) 
   
CD4    
Median (IQR) (cells/ mm3) 389 (298-545) 90 (42-147) 
≤350 210 (46.0) 247 (54.0) 
>350 295 (99.7) 1 (0.3) 
   
WHO Stage   
1 356 (78.1) 100 (21.9) 
2 72 (63.7) 41 (36.3) 
3 57 (39.9) 86 (60.1) 
4 0 (0.0) 8 (3.2) 
Missing 20 (60.6) 13 (39.4) 
   
Previous HIV diagnosis   
No 199 (66.1) 102 (33.9) 
Yes 306 (67.7) 146 (32.3) 
Abbreviations: SD=standard deviation, IQR=interquartile range. 
 
Late diagnosis versus delayed presentation to care 
 
Of those who presented to care with advanced HIV, 146 (n=59%) had been previously 
diagnosed with HIV elsewhere. This was similar to the proportion of those with a 
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previous diagnosis in the non-advanced HIV group (n=306/505; 61%; chi-square p-value 
0.650). Most participants with advanced HIV presented to care within three months of 
their initial diagnosis (102/145; 70%), including 44 individuals who presented within one 
week. The median time to presentation to HIV care after an initial diagnosis was 22 days 
(IQR 6-147) for those with advanced HIV, compared to 19 days (IQR 4-119) for those 
with non-advanced HIV (p=0.716). 
 
Factors associated with presentation to care with advanced HIV 
 
Table 3 shows the association between clinical and sociodemographic characteristics and 
presenting to care with advanced HIV. In both univariable and multivariable analyses, 
age was linearly associated with presenting to care with advanced HIV, with a final AOR 
of 1.72 (95% CI 1.42 to 2.03) per unit increase in age category, compared to the reference 
category of <30 years. Individuals presenting to the Baba Dogo clinic were more likely to 
present with advanced HIV (AOR 1.55; 95% CI 1.09-2.20) than those presenting to the 
Kibera clinic. Participants with some secondary education were less likely to present with 
advanced HIV; however, this association was of borderline significance in the final 
model (AOR 0.73; 95% CI 0.53-1.03). In the univariable analysis, male sex appeared to 
be associated with presenting with advanced HIV; however, this effect diminished in the 
multivariable analysis and did not remain in the final model. 
 
Table 3. Univariable and multivariable analysis of variables associated with 
presentation to care with advanced HIV disease, Nairobi, Kenya. 
 
 Crude ORs  Adjusted ORs  Final adjusted ORs 
Variable OR 95% CI p-value  OR 95% CI p-value  OR 95% CI p-value 
            
Age* 1.66 1.41-1.96 <0.001  1.65 1.39-1.97 <0.001  1.72 1.45-2.03 <0.001 
Presenting at 
the Baba 
Dogo clinic 
1.23 0.88-1.71 0.220  1.53 1.08-2.17 0.018  1.55 1.09-2.20 0.014 
Secondary 
education 
0.74 0.53-1.03 0.070  0.69 0.49-0.98 0.040  0.73 0.52-1.03 0.073 
Male gender 1.52 1.12-2.07 0.008  1.30 0.93-1.82 0.128     
Illicit drug 
use 
0.60 0.30-1.20 0.155  0.53 0.26-1.09 0.084     
Hazardous 
drinking 
1.04 0.74-1.44 0.835         
Travel time† 0.98 0.84-1.34 0.782         
Previous 
HIV 
diagnosis 
0.93 0.68-1.27 0.650         
Abbreviations: OR, odds ratio, CI, confidence interval. 
*OR corresponds to an increase in the odds ratio per unit increase in category     
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4.2 Gender differences in health-related quality of life at the time of a 
positive HIV test (Study II)  
Of 1068 HIV-positive individuals screened to participate in the study, 775 were recruited 
(700 for the trial and 75 for the cohort study only). Selected baseline characteristics are 
shown in Table 4. Women comprised 61% of the cohort (n=470/775). Of the recruited participants, 752 (97%) had complete baseline questionnaire, CD4, and SF-12 data. 
 
 
Table 4. Demographic and clinical characteristics of participants in the Health-
Related Quality of Life study, n=775, Nairobi, Kenya. 
 
 
Variable Women (n=470) 
n (%) 
Men (n=305) 
n (%) 
   
Age (years)   
Mean (SD) 32 (9.21) 37 (9.77) 
   
Education   
No secondary level  338 (71.9) 183 (60.0) 
At least some secondary 132 (28.1) 122 (40.0) 
   
Employment status*   
Employed 295 (71.1) 283 (93.1) 
Unemployed 120 (28.9) 21 (6.1) 
   
CD4 (cells/mm3)   
Median (IQR)  328 (168-493) 266 (135-434) 
Missing 15 (3.2) 7 (2.3) 
   
Psycho-social support   
None/little/some of the time 98 (20.9) 57 (18.7) 
Most or all of the time 372 (79.1) 248 (81.3) 
   
Alcohol use   
Non-heavy/hazardous drinking 409 (87.0) 222 (72.8) 
Heavy/hazardous drinking 61 (13.0) 83 (27.2) 
   
Illicit drug use   
Not a current drug user 455 (96.8) 272 (89.2) 
Current drug user 15 (3.2) 33 (10.8) 
Abbreviations: SD=standard deviation, IQR=interquartile range. 
*Does not include participants who are students (n-=9) or homemakers (n=47). 
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Gender differences in mental and physical composite scores 
 
The mean physical composite score (PCS) was higher in women than men (43.80 v 
41.44, mean difference 2.36, 95% CI 0.61 to 4.11). After adjustment for confounding, the 
mean difference in PCS score increased marginally (mean difference 2.49, 95% CI 0.54 
to 4.44) (Table 5). While statistically significant, this difference is not considered 
clinically important. 
 
Women had a lower crude mean mental composite score (MCS) score than men, but this 
difference was neither statistically nor clinically significant (51.98 v 53.25, mean 
difference -1.27, 95% CI -2.88 to 0.33). After adjusting for confounding, the mean 
difference was reduced (mean difference -0.99, 95% CI -2.71 to 0.73).  
 
Table 5. Unadjusted and adjusted differences in mean mental (MCS) and physical 
composite scores (PCS) (95% confidence interval) between men and women at the 
time of a positive HIV test, Nairobi, Kenya. 
 
Outcome No. Mean 
score 
Crude analysis p-value Adjusted for 
confounding 
p-value 
       
MCS       
Women 470 51.98 -1.27 (-2.88 to 0.33) 0.119 -0.99 (-2.71 to 0.73) 0.259 
Men 304 53.25     
       
PCS       
Women 470 43.80 2.36 (0.61 to 4.11) 0.008 2.49 (0.54 to 4.44) 0.012 
Men 304 41.44     
Abbreviations: MCS=mental composite score CI=confidence interval. 
PCS score adjusted for age, baseline CD4, study site, education, employment, marital status (adjusted 
model n=698). MCS score adjusted for employment, site, baseline CD4, social support, and current drug 
use (adjusted model n=698) 
 
Gender-specific factors associated with Health-Related Quality of Life 
 
Few of the factors investigated were associated with MCS in the sex-specific HRQoL 
analysis. For both men and women, being unemployed was associated with a clinically 
important decrease in MCS (men: -5.13, 95% CI-10.02 to -0.23; women -3.98, 95% CI -
6.43 to -1.54). There were no other factors significantly associated with men’s MCS. For 
women, there was a 1.42 linear increase in score per increase in CD4 category. Social 
support was also a factor in women’s MCS score, with those who felt that they had no to 
little social support having a lower score than those with greater social support 
(coefficient -2.77; 95% CI-5.46 to -0.08). 
 
Several factors were associated with physical HRQoL, and the same factors were 
associated with PCS in both men and women. Older age and unemployment were 
associated with a decrease in PCS; while having attended at least some secondary school 
and having a higher CD4 was associated with an increase in PCS. The effect of these 
factors were in the same direction and of similar magnitude for both men and women, 
apart from employment status, where being unemployed was associated with a larger 
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decrease in PCS for males than for females (males -6.90, 95% CI -11.60 to -2.20 v. 
females -3.05, 95%CI -5.56 to -0.54). 
 
4.3 Retention in clinic versus retention in care during the first year of HIV 
care (Study III) 
 
This study also involved the 700 participants recruited for the trial as well as 75 
participants ineligible for the trial, but eligible for the cohort study. Retention in clinic 
was defined as returning to the same clinic at which participants enrolled between 10 and 
14 months. Retention in care was defined as being active in HIV care at any clinic 10 to 
14 months after enrolling in HIV care. 
 
 
 
Selected baseline characteristics categorized by those who were lost to care and those 
who were retained in care are found in Table 6. 
 
Table 6. Demographic and clinical characteristics of participants in the Retention in 
Care study, n=775, Nairobi, Kenya. 
 
Variable Attrition from care at 12-
months (n=166) 
n (%) 
Retained in care at 12-
months (n=609) 
n (%) 
Sex   
Male 74 (24.3) 231 (75.7) 
Female 92 (19.6) 378 (80.4) 
   
Age (years)   
Mean (SD) 34.7 (10.8) 33.7 (9.5) 
   
Education   
No secondary school 120 (23.0) 401 (77.0) 
Some secondary school 46 (18.1) 208 (81.9) 
   
Previous HIV diagnosis   
No 72 (22.4) 249 (77.6) 
Yes 94 (20.7) 360 (79.3) 
   
CD4 (cells/mm3)   
Median (IQR)  252 (84-450) 314 (168-464) 
Missing 12 (54.54) 10 (45.45) 
   
ART eligibility at baseline   
Ineligible 43 (19.6) 176 (80.4) 
Eligible 111 (20.8) 423 (78.2) 
Missing 12 (54.54) 10 (45.45) 
   
Trial participant   
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No 28 (37.3) 47 (62.7) 
Yes 138 (19.7) 562 (80.3) 
   
Travel time to clinic   
<60 minutes 97 (16.1) 507 (83.9) 
≥60 minutes 23 (19.2) 97 (80.8) 
Missing 1 5 
Abbreviations: SD=standard deviation, IQR=interquartile range 
 
Retention in clinic versus retention in care 
 
Overall, 486/775 participants (62.7%, 95% CI 59.2% to 66.1%) were retained in clinic at 
12 months (returned to the clinic for their 12-month visit between 10 and 14 months), 
whereas 609/775 (78.6%, 95% CI 75.7% to 81.5%) were retained in care at 12 months 
(returned to the clinic for their 12-month visit or were confirmed active in care 
elsewhere). 
 
Factors associated with attrition from care 
 
In the crude analysis, presenting at the Baba Dogo clinic and being a trial versus a cohort 
study participant were associated with a reduced risk of attrition. In the multivariable 
model, being a trial participant remained strongly associated with a reduced risk of 
attrition (ARR 0.52, 95% CI 0.37 – 0.73). Compared to the baseline CD4 count category 
of 200 cells/mm3, participants in higher CD4 count categories had a reduced risk of 
attrition (ARR 0.59, 95% CI 0.40 – 0.85) for those in the 200-349 cells/mm3 CD4 count 
category, and ARR 0.61 (95% CI 0.35 – 1.08) for those in the 350-499 cells/mm3 CD4 
count category. An interactive effect between sex and travel time to clinic was not found. 
 
4.4 Effect of an interactive text-messaging service on patient retention during the 
first year of HIV care (Study IV) 
 
Of the 1068 participants screened for study participation, 700 participants were recruited 
for the trial (Figure 7). All 349 participants allocated to the intervention arm received the 
intervention, as well as one control arm participant. The analysis was intention to treat. 
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Figure 7. WelTel Retain trial: participant flow diagram 
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Table 7. Demographic and clinical characteristics of participants in the WelTel 
Retain trial, n=700, Nairobi, Kenya. 
 
Variable Control 
(n=351) 
n (%) 
SMS intervention 
(n=349) 
n (%) 
Sex (female) 213 (60.7) 206 (59.0) 
Age (years) mean (SD) 33.46 (9.44) 33.99 (10.07) 
Education   
     No formal education 9 (2.6) 12 (3.4) 
     Primary 223 (63.5) 210 (60.2) 
     Secondary 119 (33.9) 127 (36.4) 
Marital status   
     Single 54 (15.4) 56 (16.0) 
     Married 206 (58.7) 193 (55.3) 
     Widowed or divorced 91 (25.9) 100 (28.7) 
Clinic   
     Kibera 250 (71.2) 251 (71.9) 
     Baba Dogo 101 (28.8) 98 (28.1) 
Previously diagnosed with HIV 199 (56.7) 212 (60.7) 
WHO Stage   
     1 226 (64.4) 206 (59.0) 
     2 47 (13.4) 54 (15.5) 
     3 61 (17.4) 62 (17.8) 
     4 1 (0.3) 7 (2.0) 
     Missing 16 (4.6) 20 (5.7) 
CD4 (cells/mm3) median (IQR) 307 (148-468) 289 (143-449) 
     Missing 8 (2.3) 10 (2.9) 
ART eligible 237 (69.1) 251 (74.0)  
HRQoL PCS, mean (SD) 42.59 (12.10) 43.12 (11.52) 
HRQoL MCS, mean (SD) 52.13 (10.88) 53.23 (11.04) 
Travel time to clinic   
     <30 minutes 172 (49.0) 175 (50.1) 
     30-59 minutes 127 (36.2) 112 (32.1) 
     ≥60 minutes 49 (14.0) 59 (16.9) 
     Missing 3 (0.9) 3 (0.9) 
Own v. shared mobile phone 326 (92.9) 337 (96.6) 
Abbreviations: SD=standard deviation, IQR=interquartile range, HRQoL=health-related quality of life 
 
 
 
Primary and secondary outcomes 
 
In the final analysis (n=700), the intervention had no effect on the primary outcome, 
retention in care at 12-months (risk ratio [RR] 0.98, 95% CI 0.91-1.05), nor did it have an 
effect on the key secondary outcome, retention in Stage 1 HIV care (RR 0.98, 95% CI 
0.93-1.04) (Table 8). Similarly, the intervention had no effect on other retention or 
treatment outcomes such as the proportion of those who initiated treatment within three 
months, time to treatment initiation, or retention in clinic at six months (Table 8). 
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Table 8: Clinical outcomes of the WelTel Retain trial, Nairobi, Kenya. 
 
 Intervention 
(n=349) 
n (%) 
Control 
(n=351) 
n (%) 
Risk ratio 
(95% CI) 
Risk difference 
(95% CI) 
Outcome     
Primary outcome     
Retained in care at 12-months 277 (79.4) 285 (81.2) 0.98 (0.91 - 1.05) -0.02 (-0.08 – 0.04) 
Key secondary outcome     
Retained in Stage 1* care 302 (86.5) 310 (88.3) 0.98 (0.93-1.04) -0.02 (-0.07 - 0.03) 
Secondary outcomes     
Initiated ART in a timely 
manner 
207/251 
(82.5) 
186/237 
(78.5) 
1.05 (0.96 – 1.15) 0.04 (-0.03 - 0.11) 
Retained in clinic at 6 months 227 (65.0) 225 (64.1) 1.02 (0.91 – 1.13) 0.01 (-0.06 – 0.08) 
Retained in clinic at 12 
months 
230 (65.9) 222 (63.2) 1.04 (0.93 – 1.16) 0.03 (-0.04 – 0.10) 
Death (all-cause)  27 (7.7) 22 (6.3) 1.23 (0.72 - 2.12) 0.02 (-0.02 – 0.05) 
Abbreviations: CI=confidence interval 
*participant returns to the clinic to receive the first CD4 count results 
 
Satisfaction with care was similar between the two groups (Table 9). Although the 
median and interquartile range was the same in both groups for social support, 
intervention arm participants had a higher mean rank social support score than the control 
group (228.78 v. 206.97), indicating greater perceived social support in the intervention 
group (Table 9). PCS and MSC HRQoL scores were also greater in the intervention 
group than the control group, with a mean difference of 2.27 in PCS (95% CI 1.00 to 
3.53) and 1.86 (95% CI 0.56 to 3.15) in MCS. 
 
Table 9: Outcomes based on 12-month follow-up questionnaire data in the WelTel 
Retain trial, Nairobi, Kenya. 
 
 Intervention 
(n=220) 
Control 
(n=215) 
Effect estimate 
(95% CI) or test 
statistic 
p-value 
Outcome     
Satisfaction with care* (median, Q1-Q3) 7 (7-7) 7 (7-7) 0.91 (Chi square) 0.34 
Level of social support† (median, Q1-Q3) 5 (4-5) 5 (4-5) 4.91 (Chi square) 0.027 
Health-related quality of life     
Physical composite score (mean, SD) 53.28 (4.68) 51.01 (8.32)‡ 2.27 (0.10 to 3.53) 0.001 
Mental composite score (mean, SD) 57.17 (5.53) 55.32 (7.97) ‡ 1.86 (0.56 to 3.15) 0.005 
Abbreviations: CI=confidence interval, Q1-Q3=quartile 1-quartile 3, SD=standard deviation 
*Kruskal-Wallis χ2 (1 df) 0.912; control n=215 intervention n=220, mean rank control=213.80; 
intervention=222.11 
†Kruskal-Wallis χ2 (1 df) 4.910; control n=215 intervention n=220, mean rank control=206.97; 
intervention=228.78 
‡n=214 
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Subgroup effects 
 
There were no significant sub-group effects. 
 
Adverse Events 
 
An intervention arm participant had a mild adverse event related to the intervention, in a 
which their partner became suspicious of the weekly text messages and follow-up calls. 
They withdrew from the study. 
 
Patient-perceived benefits and barriers to the intervention 
 
Overall, most intervention arm participants who completed the follow-up questionnaire 
were pleased with the service and its frequency of delivery. Most (75% [n=165/220]) 
reported no barriers to the intervention. Barriers noted included lack of network credit 
(n=22/220, 10%) and phone access (n=12/220, 5.5%). Greatest perceived benefits were 
convenient access to care and advice (n=88/219, 40.2%); regular contact with healthcare 
providers (n=54/219, 24.7%); and feelings of care, support or security (n=42/218, 
19.2%).   
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5. DISCUSSION  
5.1 Standardizing definitions and outcomes across studies 
 
When reviewing the literature for both Study I, presentation to care with advanced HIV, 
and Study II, a gender comparison of HRQoL, comparison between previous studies was 
hindered by the lack of consistent definitions used for outcomes. Studies in sub-Saharan 
Africa on late presentation and presenting with advanced HIV have used definitions 
based on CD4 count, such as ≤100 cells/mm3 (40) or <100 cells/mm3 (41); definitions 
based on categorization by clinical features, such as CDC B or CDC C (42), or WHO 
Stage 3 or 4 (43). Some researchers have used a combination of the two, for example 
WHO Stage 3 or 4 or a CD4 count less than 200 cells/mm3 (44). Of the eight studies 
included in the literature review for the study on advanced HIV at presentation to HIV 
care, no two studies used the same definition. A lack of common definitions of outcomes 
prevents direct comparisons between regions and time periods and makes it difficult to 
evaluate the impact of interventions designed to target presenting to care with advanced 
HIV. Although definitions of outcomes may at times been driven by resource constraints 
i.e. a lack of laboratory testing in poor settings, where it is not, it would be helpful to 
have standardized definitions in place. 
 
This problem is not exclusive to sub-Saharan Africa, Antinori et al note that there have 
been more than 20 definitions of a “late presenter” used in the literature across Europe 
and elsewhere (45). They propose the following consensus definition of late presentation: 
persons presenting for care with a CD4 count <350 cells/mm3 or with an AIDS-defining 
event, regardless of CD4 count. They define presentation with advanced HIV disease as 
presenting to care with a CD4 count <200 cells/ mm3 or presenting with an AIDS-
defining event, regardless of CD4 count (45). Antinori et al suggest that if researchers 
prefer to use alternative definitions, that the consensus definitions are presented alongside 
their chosen ones. However, this may create problems associated with multiple outcomes, 
such as spurious conclusions. If researchers and others choose alternative definitions, 
data should be presented in such a way as to allow others to estimate the proportion of 
individuals presenting late to care and with advanced HIV. This would enhance 
comparability between studies and help to move the field forward. 
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5.2 The importance of measuring ‘retention in care’ versus ‘retention in 
clinic’ to estimate retention in HIV care  
There have been numerous papers estimating retention in HIV care and many meta-
analyses done. In sub-Saharan Africa alone, a systematic review published in 2011 
included 28 studies from the region on retention in individuals for the time between 
testing positive for HIV and initiating treatment (14). For individuals on treatment, a 
systematic review by these same authors in 2007 included 33 studies (22). The studies 
included in these meta-analyses equated “retention in care” with “retention in clinic”; 
however, there is a large and important difference between the two. Geng et al 
highlighted this difference in their publication “Retention in care among HIV-infected 
patients in limited-resource settings: emerging insights and new directions” (18). Rather 
than viewing retention in care from a clinic-based perspective, i.e. an individual is 
considered retained if they come back to the clinic at which they were originally enrolled 
in HIV care, they considered retention in care from a patient-based perspective, in which 
a patient is considered to be retained in care regardless of whether they are active in care 
at the clinic at which they originally enrolled or active in HIV care at another clinic. 
 
In Kibera, one of our study settings with an area of just 2.38 km2, there were several other 
clinics that provided HIV care to where study participants may have switched their care. 
In addition, our study population was highly transient, so they might have also sought 
care in their village or hometowns, or in a new location entirely. The decentralization of 
HIV care in many sub-Saharan African countries has meant that individuals with HIV 
may have many options for HIV care. Estimating retention in care by using retention in 
clinic as a proxy measure may underestimate retention in care, as an individual who does 
not return to the clinic where surveillance or a study is being conducted may not 
necessarily be lost to care, but instead may be engaged in care at another clinic. 
Individuals may also transfer their care formally, or informally (‘silent transfers’), but 
unless these individuals are traced at the time point of interest, there is no way of 
knowing whether they are active in HIV care. 
 
Both in our trial and cohort study, retention in care was substantially greater than 
retention in clinic. Among trial participants, retention in clinic was 65% (n=452/700), 
while retention in care was 80% (n=562/700) (46). When the cohort participants (n=75) 
were added to the trial population, 63% (n=486/775) were retained in clinic, while 79% 
(n=609/775) were retained in care (47). To quantify retention in care at 12 months, we 
actively traced, by telephone or in the community, every participant who did not return to 
the clinic at which they were originally enrolled to determine whether they were active in 
HIV care or not. In the cohort study, of 289 participants who required further 
investigation to determine their status, 43% (n=123) were found to be active in care at 
another clinic (47). This highlights how important participant tracing is to quantify 
retention in care, particularly in settings where there are multiple clinics at which 
individuals may seek their care, or when investigating retention in care among transient 
populations. 
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When I designed the cohort study to quantify retention in care, to the best of my 
knowledge, there was only one other study that estimated retention in care beyond 
retention in clinic. In this Ugandan study, a sampling-based approach was used to 
estimate retention in care using assumptions based on the vital status of those who did not 
return to the clinic (25). A tracker community traced a sample of 128 participants out of 
829 who did not return to the clinic to estimate retention in care (25). Estimates of 
retention in care at 12 months in the Ugandan study were based on one of two scenarios: 
assuming all patients who were determined to be alive in the sample were retained in care 
and extrapolating this to estimate retention in care, which increased the estimate of 
retention in care to 90.9% from 82.3% who were retained in clinic; or alternatively, 
assuming all patients who were found alive were no longer in HIV care, which increased 
the estimate of retention in care to 85.8% from 82.3%. (These estimates included updated 
information from a short questionnaire on participants’ care status administered at the 
time the tracker made contact with the participant.) 
 
Since the Ugandan study, and while our study was underway, others have acknowledged 
the deficiencies of using retention in clinic as a proxy measure for retention in care, and 
they have conducted investigations to obtain more accurate estimates of retention. A 
large study in South Africa using National Health Laboratory Service data that involved 
55,836 patients measured 6-year retention in clinic at 29%, whereas retention in care at 6 
years was 63% (26). In a further study by Geng et al involving adults on ART in 14 
clinics from Uganda, Tanzania and Kenya (21), retention in clinic at two years was 69%. 
After accounting for informal and formal transfers, the authors found that 83% were 
retained in care. Again, a substantial increase from retention estimates that only 
considered individuals who returned to their original clinic. Although it was thought that 
retention in clinic likely presented an underestimate of retention in HIV care, there was 
some thought that it may overestimate retention, as estimates typically come from larger, 
well-resourced clinics (26). These recent studies, together with ours, confirm that 
retention in clinic substantially overstates attrition, and underestimates retention in HIV 
care. 
 
5.3 Mobile phone interventions to promote retention in HIV care 
 
When this study began, there were no other studies that had been published examining 
whether text-messages could be used to promote retention in HIV care. While the WelTel 
Retain trial was underway, a trial in Mozambique using one-way text messages as 
appointment reminders concluded that they had no effect on retention in HIV care at 12 
months (30). Using a shorter time frame, a before-and-after study in Swaziland found that 
one-way text messages did not improve the proportion of patients who returned to collect 
their CD4 results (31). Similarly, studies that have tested using text messages as 
appointment reminders outside of Africa have also failed to demonstrate effectiveness 
(32,33). In Africa, interactive text messaging and mobile phone calls have been 
successful in engaging mothers in care in PMTCT programmes (34,35). A study currently 
underway in Kenya that tests the same intervention (WelTel) examined in our study will 
provide further information on the effectiveness of mHealth interventions to retain 
mothers in PMTCT care (48).  
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Overall, based upon the available evidence, it appears that when text messages are used 
as appointment reminders, they fail to improve clinic attendance. Among PMTCT 
populations, patient engagement with text messages and mobile phone calls may be 
effective at retaining mothers in PMTCT programmes, at least in some sub-Saharan 
African settings. Our trial suggests that contrary to our hypothesis, two-way text 
messaging is not an effective intervention to improve retention in care during the first 
year of HIV care in a general HIV population, as we did not find an effect on Stage 1 care 
(patient returns to receive their CD4 text results), 6-month retention in clinic, or in 
retention in care at 12-months. There have been no other rigorous trials investigating 
mHealth interventions as tools to promote engagement in HIV care. 
 
Our hypothesis was based on findings of a post-trial analysis of the WelTel Kenya1 data. 
WelTel Kenya1 investigated the effect of the intervention on adherence to ART at three 
clinics in Kenya (49). After the trial, we conducted an analysis of the data to determine 
factors associated with retention in clinic at twelve months (50). The odds ratio for the 
association between the intervention and attrition was 0.72 (95% CI 0.43-1.18, p-value 
0.189) (50). Although the finding was not statistically significant, we believed the 
reduced odds of attrition among those who had received the intervention warranted 
further investigation in a separate trial. 
 
The findings of the WelTel Retain trial should taken into consideration the study’s 
context. Retention in care at the clinics involved in the trial was unexpectedly high (81% 
in the control group). If the trial had been conducted at clinics where baseline retention in 
care was substantially lower, then room for improvement would have been greater, and 
the intervention may have been more likely to have an effect (if it served to mitigate 
barriers to coming to the clinic). In addition, the two clinics involved in the trial had 
clinical procedures in place to encourage retention, which would have increased retention 
in care among all patients and in both arms, regardless of the intervention. Individuals 
who missed a clinic appointment were called up to two times to reschedule the 
appointment. The intervention may have been more effective at clinics where there were 
no such measures in place. Finally, of the studies involving the intervention so far, the 
WelTel Retain trial had the highest proportion of non-response to messages sent (44%) 
(46). In the WelTel Kenya1 study, there was no response to 32% of messages sent (49). 
The clinics involved in the WelTel Retain trial were in extremely poor settings, in which 
participants cited reasons such as insufficient credit or a broken phone for not responding 
to the messages (46). It is possible that in a setting in which participants are able to more 
fully engage in the service, it may have been more likely to have been effective. 
 
5.4 Trials with null findings 
 
Publication bias towards studies with positive findings arises from both journals and 
scientists themselves. Editors may favour studies with positive results as they are cited 
more frequently, raising a journal’s impact factor. Researchers may choose not to report 
their null findings for various reasons, including lack of priority and time; the perception 
that studies with negative or null findings are less likely to be accepted for publication; 
and having a personal or industry-sponsored stake in their findings (51). Together with 
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the publication of the WelTel Retain trial findings in The Lancet Public Health, Fox and 
Kaufman commented on the importance of publishing null findings (52), arguing that it is 
as important to know whether an intervention has an effect, as it is to know whether an 
intervention has no effect. This is particularly true for rigorously conducted, adequately 
powered studies that produce valid and precise findings. 
 
The importance of having a published or publicly available study protocol with pre-
determined outcomes cannot be understated. In a study with null findings, it prevents 
authors from data dredging or data HARKing (Hypothesizing After the Results are 
Known) (53). In this trial, and consist with the CONSORT guidelines, the study team 
reported the trial outcomes in accordance with the published study protocol and 
ClinicalTrials.gov record. Any additional outcomes reported are highlighted in the 
published manuscript, together with the reason for reporting these outcomes. Any 
outcomes not listed in the protocol were decided upon before the data were analysed. 
During the manuscript review, the journal did an excellent job of ensuring that the 
outcomes reported were consistent with the published trial protocol (54) as well the 
CONSORT guidelines (55). 
 
When the WelTel Retain trial started in 2013, ART eligibility was based on a CD4 count 
of 350 cells/mm3; therefore, there was a period of pre-ART care for many individuals. 
During pre-ART care, individuals were most at risk of attrition, compared to those on 
ART. We were particularly interested in seeing whether the intervention could improve 
retention during this critical period in the continuum of HIV care. Over the course of the 
trial, the CD4 threshold for treatment was increased to 500 cells/mm3, and in 2016, the 
WHO guidelines recommended a “treat-all” strategy, in which treatment should be 
offered to all persons who test positive for HIV regardless of CD4 their count (56). With 
the implementation of these new guidelines, the pre-ART period essentially vanished; 
however, retention in care, even among those who are on ART, remains an important 
issue that must be tackled to meet the UNAIDS 90-90-90 targets. 
 
While the WelTel intervention was not found to be effective at promoting retention in 
care, a previous trial demonstrated that the service improved adherence to ART at 12 
months. The findings from the two trials are not necessarily conflictual, despite null 
findings in one and positive findings in the other. If two groups are equally well retained 
in care, and one receives the intervention while the other does not, it is possible that they 
might have differing levels of adherence. So, while the findings from the WelTel Retain 
trial did not suggest an effect on retention in care in this setting, the intervention may still 
provide benefit to those with HIV in other ways, such as improved ART adherence and 
greater perceived support by patients from the clinic. 
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6. CONCLUSIONS 
 
The WelTel Retain study, with its large sample size and comprehensive datasets, allowed 
for multiple investigations. The inclusion of those who were ineligible for the trial in a 
larger cohort allowed for more generalizable investigations than that which could have 
been conducted using a trial population alone. Studies included whether delayed 
diagnosis or delayed presentation to care after diagnosis may lead to presenting to care 
with advanced HIV; an analysis of gender differences in HRQoL at the time of diagnosis; 
and a quantification of ‘retention in care’ without having to rely on ‘retention in clinic’ as 
a proxy measure. The trial itself was the first rigorous study evaluating the effect of an 
interactive mHealth intervention on retention in care in an adult HIV population. 
 
Using baseline data, we found that presentation to care with advanced HIV was primarily 
due to delayed diagnosis, rather than delayed linkage to care after diagnosis. In the 
second study, we found that men and women have similar self-perceived quality of life 
scores in mental health, with unemployment being associated with a clinically significant 
decrease in mental health in both genders. Women reported greater physical health, but 
the difference was not considered clinically important, and the factors related to physical 
health, such as a higher CD4 count, were similar for both genders. Both the cohort study 
focussing on retention in care and the trial demonstrated that in this setting, retention in 
clinic substantially underestimated retention in care. Although the WelTel intervention 
was well-received by participants, it did not improve retention during the first year of 
HIV care. New ways to improve retention in care for people living with HIV are 
required, particularly at the start of the cascade of HIV care.    
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7. RESEARCH AND POLICY IMPLICATIONS  
Study I 
Study I highlights the numerous definitions of ‘late presentation to care’ and ‘advanced 
HIV’ that have been used in the literature. To improve comparability across studies and 
over time, it is important that researchers use consistent definitions for these terms, which 
may be aided by the publication of consensus definitions for these terms (45). Even if 
researchers choose to use their own definitions, data should be presented in such a way as 
to allow others to estimate the proportion of individuals presenting late to care and with 
advanced HIV. 
 
At the clinics involved in the study, presenting to care with advanced HIV appeared to be 
largely due to delayed diagnosis, rather than delays in seeking care after diagnosis. 
Variation by clinic suggests that outreach and other community-based efforts may drive 
earlier testing and linkage to care. Our findings highlight the ongoing importance of 
implementing strategies to encourage earlier HIV diagnosis, particularly among adults 30 
years and older. To fulfil the new global HIV targets, efforts are needed to maximize 
earlier diagnosis and entry into care at the front end of the HIV care continuum. 
Otherwise, changing guidelines to recommend treatment earlier in the course of HIV 
infection will not achieve their intended outcomes. 
 
Study II 
 
This study was the first gendered analyses of HRQoL related to people with HIV in sub-
Saharan Africa. As such, its findings need to be confirmed (or refuted) in further 
investigations. This study highlights the need for consistent use of validated instruments 
to measure HRQoL and rigorous studies that control for confounding. Given the strong 
association between unemployment and both mental and physical health, broader 
economic development in conjunction with HIV-specific workplace policies and 
programmes to prohibit discrimination in the workplace are required. Overall, differences 
between the genders in factors related to HRQoL, such as social support, should be 
considered in public health policy and interventions to improve HRQoL in those living 
with HIV. 
 
Study III 
 
Study III highlights the need for tracing studies and adequate tracing and attrition 
monitoring systems within routine HIV care to more accurately quantify retention in HIV 
care and reduce loss to follow-up from HIV programmes in sub-Saharan Africa. This 
study, together with the trial, demonstrate that ‘retention in clinic’ is a poor proxy for 
‘retention in HIV care’. Methods that track patient care between clinics, including silent 
transfers, are required to more accurately estimate retention in care. Our findings are 
positive in that a greater proportion of people living with HIV were retained in care than 
was expected; however, our estimate of retention in care falls short of the level of 
retention required to fulfil the UNAIDS 90-90-90 targets. New interventions and 
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innovative health systems solutions are required to better retain people in HIV care as 
well as to bring back those clients who drop out of care. 
 
Study IV 
 
Throughout the course of the WelTel Retain trial, ART eligibility guidelines changed, 
bringing into question whether the millions of people now eligible for ART will have the 
same barriers to adherence and retention as under previous guidelines. To meet the 
UNAIDS HIV targets, these barriers must be investigated and addressed. The WHO 
suggested the use of text messaging to improve retention in HIV care, both specifically 
from enrolment in care to ART eligibility and for lifelong retention. This trial 
demonstrated that the WelTel service did not improve retention during the first year in 
HIV care, either from the time to diagnosis to ART eligibility or at 12-months. For this, 
new ways to improve retention in care in adult HIV populations are required, particularly 
at the start of the cascade of HIV care. In populations who are retained, evidence-based 
SMS interventions, including WelTel, could be used to improve adherence, which 
supports the second and third UNAIDS targets to have 90% of people who know their 
status on ART and 90% of those virally suppressed. 
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10. APPENDIX  
World Health Organization clinical staging of HIV/AIDS for Adults  
Clinical stage 1 
 
Asymptomatic 
Persistent generalized lymphadenopathy (PGL) 
 
Clinical stage 2 
 
Moderate unexplained weight loss (10% of presumed or measured body weight) 
Recurrent respiratory tract infections (RTIs, sinusitis, bronchitis, otitis media, 
pharyngitis) 
Herpes zoster 
Angular cheilitis 
Recurrent oral ulcerations 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections of fingers 
 
Clinical stage 3 
 
Conditions where a presumptive diagnosis can be made on the basis of clinical signs or 
simple investigations 
Severe weight loss (>10% of presumed or measured body weight) 
Unexplained chronic diarrhoea for longer than one month 
Unexplained persistent fever (intermittent or constant for longer than one month) 
Oral candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis (TB) diagnosed in last two years 
Severe presumed bacterial infections (e.g. pneumonia, empyema, pyomyositis, bone or 
joint infection, meningitis, bacteraemia) 
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
 
Conditions where confirmatory diagnostic testing is necessary 
Unexplained anaemia (<8 g/dl), and or neutropenia (<500/mm3) and or thrombocytopenia 
(<50 000/ mm3) for more than one month 
 
Clinical stage 4 
 
Conditions where a presumptive diagnosis can be made on the basis of clinical signs or 
simple investigations 
HIV wasting syndrome 
Pneumocystis pneumonia 
  
Recurrent severe or radiological bacterial pneumonia 
Chronic herpes simplex infection (orolabial, genital or anorectal of more than one 
month’s duration) 
Oesophageal candidiasis 
Extrapulmonary TB 
Kaposi’s sarcoma 
Central nervous system (CNS) toxoplasmosis 
HIV encephalopathy 
 
Conditions where confirmatory diagnostic testing is necessary: 
Extrapulmonary cryptococcosis including meningitis 
Disseminated non-tuberculous mycobacteria infection 
Progressive multifocal leukoencephalopathy (PML) 
Candida of trachea, bronchi or lungs 
Cryptosporidiosis 
Isosporiasis 
Visceral herpes simplex infection 
Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or 
lymph nodes) 
Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, penicilliosis) 
Recurrent non-typhoidal salmonella septicaemia 
Lymphoma (cerebral or B cell non-Hodgkin) 
Invasive cervical carcinoma 
Visceral leishmaniasis 
 
Reference: World Health Organization (WHO). Interim WHO clinical staging of 
HIV/AIDS and HIV/AIDS case definitions for surveillance [Internet]. 2005 [cited 2019 
Apr 8].Available from: https://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf?ua=1 
